PASG PASG
Company Profile ↓Company Overview
PASG (PASG) is a publicly traded company listed on with a market capitalization of $14.67M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -19.69% |
| 6 Months: | -58.05% |
| 3 Months: | +7.96% |
| 1 Month: | -7.80% |
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)44.20 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 76.8% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 13.82M | 10.33M | 8.65M | 10.34M | 8.88M |
| Operating Income | - | -7.77M | -11.64M | -17.91M | -27.30M | -28.63M | -38.93M | -48.53M | -47.10M | -42.81M | -39.81M | -27.53M | -35.88M | -25.39M | -28.67M | -18.05M | -17.38M | -20.70M | - | -13.82M | -10.33M | -8.65M | -10.34M | -8.88M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -13.62M | -10.16M | -8.47M | -10.16M | -8.75M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -15.40M | -9.38M | -7.75M | -12.98M | -7.56M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -7.67M | -13.43M | -11.39M | -17.59M | -27.17M | -28.53M | -38.88M | -48.44M | -46.91M | -42.81M | -39.54M | -26.70M | -34.34M | -23.86M | -27.11M | -16.71M | -15.99M | -19.34M | - | -15.40M | -9.38M | -7.75M | -12.98M | -7.56M |
| Diluted EPS | - | - | - | - | - | - | -0.76 | -0.90 | -0.87 | -0.79 | -0.73 | -0.49 | -0.63 | -0.44 | -0.49 | -0.30 | -5.09 | -6.15 | - | -4.87 | -2.96 | -2.44 | - | -2.36 |
| R&D Expense | - | - | - | 13.12M | - | - | - | - | - | - | - | - | - | - | - | 11.54M | 10.43M | 8.66M | - | 7.74M | 5.81M | 4.31M | - | 4.09M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | 135.39M | 103.00M | 65.17M | 43.15M |
| Operating Income | -37.19M | -112.90M | - | -135.39M | -103.00M | -65.17M | -43.15M |
| EBITDA | - | - | - | -131.72M | -99.28M | -62.09M | -42.42M |
| Interest Expense | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | -136.12M | -102.06M | -64.77M | -45.52M |
| Tax Provision | - | - | - | - | - | - | - |
| Net Income | -45.63M | -112.23M | - | -136.12M | -102.06M | -64.77M | -45.52M |
| Diluted EPS | - | -2.91 | - | -50.00 | -37.20 | -21.40 | -14.35 |
| R&D Expense | - | - | - | - | 61.42M | 40.18M | 23.28M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 178.61M | 328.01M | - | 243.55M | 150.54M | 102.41M | 62.28M |
| Current Assets | - | - | - | - | 197.04M | 117.96M | 78.81M | 47.76M |
| Cash & Equivalents | - | 158.87M | 135.00M | - | 34.60M | 21.71M | 37.57M | 46.30M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 4.26M | 23.29M | - | 42.18M | 39.26M | 41.15M | 43.53M |
| Current Liabilities | - | 3.68M | 21.18M | - | 18.35M | 16.34M | 19.36M | 23.08M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 27.11M | 26.29M | 25.48M | 24.01M |
| Total Equity | -12.17M | -56.25M | 304.71M | - | 201.37M | 111.28M | 61.26M | 18.75M |
| Shares Outstanding | - | - | - | - | 2.73M | 2.75M | 3.10M | 3.18M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -39.90M | -80.52M | - | -118.21M | -78.26M | -47.96M | -31.51M |
| Investing Cash Flow | -1.69M | -172.11M | - | 25.20M | 65.24M | 54.95M | 40.22M |
| Financing Cash Flow | 175.60M | 228.75M | - | -1.35M | 135.00K | 8.87M | 23.00K |
| Capital Expenditure | - | - | -25.64M | -5.27M | -146.00K | -34.00K | - |
| Free Cash Flow | - | - | - | -123.48M | -78.41M | -47.99M | -31.51M |
| Net Change in Cash | - | - | - | -94.36M | -12.89M | 15.86M | 8.73M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - |
| Net Margin % | - | - | - | - | - | - | - |
| ROE % | 81.1% | -36.8% | - | -67.6% | -91.7% | -105.7% | -242.7% |
| ROCE % | -21.3% | -36.8% | - | -60.1% | -76.7% | -78.5% | -110.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for PASG
Remix to go public in reverse merger with once high-flying Passage Bio
The transaction marks the latest turn in the fortunes of Passage Bio, one of the companies started by gene therapy pioneer Jim Wilson.
SPRY, PASG, BOXL: Why These Stocks Plunged Double Digits In After-Hours Trading Today
The after-hours decline was driven by concerns over trading activity, business performance and company restructuring plans.
PASG Stock Slumps 16% After-Hours — What’s Driving The Selloff?
Passage Bio said on Wednesday that it will merge with privately held Remix Therapeutics.
Passage Bio and Remix Therapeutics Announce Merger Agreement
Combined company to operate as Remix Therapeutics and advance Remix’s pipeline of novel small molecule therapies designed to reprogram RNA processing and address disease drivers at their origin Remix’s lead program, REM-422, is an orally av…
Passage Bio Inc (PASG) Stock: Should You Buy the Dip For 125% Upside?
Passage Bio Inc (NASDAQ:PASG) is one of the best gene therapy stocks to buy in 2026. While the stock is down around 50% year-to-date, analysts see it surging 125% over the next 12 months. On April 20, Passage Bio said it was reviewing its s…
Sector Update: Health Care Stocks Softer Late Afternoon
Health care stocks declined late Tuesday afternoon, with the NYSE Health Care Index down 1% and the
PASG — Frequently Asked Questions
What is the current share price of PASG?
As of 2026-08-05 17:25 PDT, PASG trades at $4.61 on NASDAQ/NYSE. Its 52-week range is $4.08 to $19.85.
What is the market capitalisation of PASG?
PASG has a market capitalisation of $14.67M on NASDAQ/NYSE.
What is the P/E ratio of PASG?
PASG trades at a trailing price-to-earnings (P/E) ratio of -0.32. Its price-to-book (P/B) ratio is 0.78.
Is PASG a good stock to buy?
This page provides a data-driven analysis of PASG, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.